AlphAIalphai — Financial news for AI agents
StockBasic Materials · Chemicals

$ASPI

ASP Isotopes Inc.

Price · $ASPIvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $ASPI in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $ASPI in the last 30 days.

Top stories · $ASPIMore →
APR 13·Stock TitanMed

$333M cash backs ASP Isotopes' 2026 push for first sales

ASP Isotopes (ASPI) provided a business update, announcing intentions for first commercial isotope shipments in 2026 for Silicon-28, Carbon-14, and Ytterbium-176, alongside achieving Helium Phase 1 nameplate capacity in Q3 2026. The company reported $333 million in cash and equivalents as of December 31, 2025, with product revenue of $5.7 million in 2025, and reiterated a long-term EBITDA target of over $300 million by 2031. Net loss for 2025 was $175.1 million, despite raising over $345 million in capital.

MAR 6·ACCESS Newswire

The Metals Company and ASP Isotopes Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

RedChip Companies will broadcast interviews with The Metals Company (Nasdaq:TMC) and ASP Isotopes (Nasdaq:ASPI) on its "Small Stocks, Big Money™" show on Bloomberg TV. The interviews, featuring TMC's CFO discussing critical mineral dependence and ASP Isotopes' CEO on stable isotopes and nuclear fuels, will air on Saturday, March 7, at 7 p.m. Eastern Time. Both companies are RedChip clients, and the discussions will cover their strategic market positions and advancements.

JAN 31·TipRanks

ASP Isotopes Makes Strategic Equity Investment in Opeongo

ASP Isotopes Inc. (ASPI) has made a strategic equity investment in biotechnology company Opeongo, Inc., purchasing over 4.3 million Series Seed-1 preferred shares on January 26, 2026. This investment provides ASP Isotopes with a significant stake in Opeongo, which develops therapeutics for fibrosis, inflammation, and cancer, and secures key investor rights including governance, veto, and a right of first offer on medical isotope supply for Opeongo's future drug programs. Despite rapid revenue growth, TipRanks' AI Analyst, Spark, rates ASPI as Neutral due to weak financial fundamentals like net losses and high leverage.

News on $ASPI

All news →